Navigation Links
Wellspring Biosciences Founder Publishes In Nature On Discovery of Small Molecule Inhibitors of K-Ras
Date:11/20/2013

LA JOLLA, Calif., Nov. 20, 2013 /PRNewswire/ -- Wellspring Biosciences, a leading biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of cancer, announced today a publication from Kevan Shokat, Ph.D., one of its founders and chairman of its scientific advisory board, in the journal Nature that describes the discovery of small molecules that bind irreversibly to a common oncogenic mutant, K-Ras G12C.

Ras genes are mutated in up to 30% of human cancers and are among the most important therapeutic targets in the treatment of human cancer.  Yet, to date, not a single drug that targets Ras proteins or acts on Ras-driven cancers has been developed successfully.  Indeed, tumors harboring Ras mutations are among the most difficult to treat and are excluded from treatment with many therapies.

Dr. Shokat serves as Professor and Chair in the Department of Cellular and Molecular Pharmacology at UCSF as well as Investigator, Howard Hughes Medical Institute.  "We are extremely excited to find a druggable binding pocket on K-Ras, the most frequently mutated oncogene in human cancer" said Professor Shokat.  "Our findings can serve as the starting point for drug-discovery efforts targeting the G12C form of K-Ras and eventually other cancer causing alleles of K-Ras."

"The proto-oncogene K-Ras is mutated in a wide array of human cancers, most of which are aggressive and respond poorly to standard therapies," said Yi Liu, Ph.D., Chief Scientific Officer of Wellspring Biosciences.  "This represents one of the most promising approaches to target K-Ras yet reported, and we look forward to continuing to advance this exciting science in the potentially transformative area of drug development."

In February 2013, Wellspring Biosciences, through its affiliate Araxes Pharma, entered into an exclusive arrangement with Janssen Biotech, Inc. to develop first-in-class therapeutics against G12C K-Ras for the treatment of cancer.  Under the agreement, Araxes Pharma will advance the program through Phase I to clinical proof-of-concept.  Thereafter, Janssen has an option for the continued development and worldwide commercialization of products arising under the agreement.

The paper, titled "Inhibitors of K-Ras G12C allosterically control GTP affinity and effector interactions" was made available on November 20, 2013 in the advanced online publication of Nature at http://dx.doi.org/10.1038/nature12796.

About Wellspring Biosciences

Wellspring Biosciences LLC is a privately held, drug discovery and development company committed to creating breakthrough medicines for the treatment of cancer and other serious diseases.  Our team has a proven track record, having previously played pivotal roles in the discovery of clinical-stage compounds for the treatment of cancer and immune-mediated inflammatory diseases at Intellikine.  Araxes Pharma LLC, an affiliate of Wellspring Biosciences, is engaged in an exclusive arrangement with Janssen Biotech, Inc.  Wellspring Biosciences is located in La Jolla, California.  For more information, please visit the company's website at www.wellspringbiosciences.com.

Contact: Anna Nadolski, 858-500-8803, anna@wellspringbiosciences.com


'/>"/>
SOURCE Wellspring Biosciences LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Springer will publish lecture series with the Mathematical Biosciences Institute
2. Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation
3. Inflection Biosciences licenses preclinical oncology programs from the CNIO
4. Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement For Plasmid DNA Production
5. 3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
6. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
7. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
8. Alfred Russel Wallace: Co-founder of the theory of biological evolution
9. Google, Intel founders support undersea research by UMass Amherst microbiologist
10. Dr. Anurag Agrawal to give Founders Memorial lecture at Entomology 2013
11. Biophysical Society names 2013 Distinguished Service, Emily M. Gray, and Founders awardees
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in ... ... combined in one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification ... Used combined in one project, multi-biometric solutions provide a ... ...
(Date:3/7/2017)... Brandwatch , the leading social intelligence company, today ... to uncover insights to support its reporting, help direct future ... UK,s leading youth charity will be using Brandwatch Analytics social listening ... better understanding of the topics and issues that are a priority ... ...
(Date:3/2/2017)... 2, 2017 Summary This report ... Merck KGaA and its partnering interests and activities since ... Description The Partnering Deals and Alliance since 2010 ... of one of the world,s leading life sciences companies. ... purchase to ensure inclusion of the most up to ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... WuXi Biologics, a leading open-access R&D ... and a WuXi AppTec Affiliate, today announced that ... Excellence Award from IMAPAC, a leading consulting firm. ... recognize outstanding leaders and trend-setters of today, and ... biomanufacturing experts in the industry, along with the ...
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, ... oncology and drug-delivery therapies, today announced that an ... and Drug Administration voted 11 to 0 that ... skin) injection was favorable for patients in the ... lymphoma and chronic lymphocytic leukemia. The FDA action ...
(Date:3/29/2017)... Research and Markets has announced the addition ... Industry Forecast to 2025" report to their offering. ... The Global Agricultural Chelates ... over the next decade to reach approximately $825.4 million by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/29/2017)... , March 29, 2017 The Global Microfluidic ... report is a specialized and comprehensive study on the existing state ... America , Europe and ... Middle East and Africa . ... Browse 172 Tables and ...
Breaking Biology Technology: